National Pharmaceutical Council (NPC) said Eli Lilly joined earlier this year. NPC conducts research on topics like the challenges of individual patient treatment effects, utilization of real-world evidence and comparative effectiveness research.

In a statement, Mark Nagy, Lilly VP, global patient outcomes and real world evidence, said, “With the full implementation of the Affordable Care Act, access to healthcare and medicines is becoming a reality for more Americans, while at the same time the personalization of drug treatments is beginning to become a reality. These changes are sparking new conversations and challenges, and I look forward to working with NPC to address them.”

Nagy will serve as Lilly’s representative on the NPC board of directors.